Introduction {#s1}
============

Stroke is globally recognized as a leading cause for mortality and adult disability. While the advent of intravenous thrombolysis and recanalization has significantly improved the outcome of stroke, a significant proportion of patients persist to suffer from deficits and disabilities. This is partly explained by the course of stroke itself, but also depending on neurological and medical complications ([@B1]--[@B3]). Prognosis and precise prediction of outcome remains challenging, especially during the hyperacute phase of the disease. While demographic and clinical characteristics, such as i.e., age and severity of acute clinical syndrome, allow for an educated guess ([@B4]), the accuracy of prediction is limited ([@B5]). For the post-acute phase of the disease, recent progress has been made in prediction of motor and cognitive recovery ([@B6], [@B7]).

Development of more accurate scores to predict outcome in the acute setting may benefit from the inclusion of biomarkers. While individual association of sanguine parameters with stroke characteristics and functional outcome has been reported, no single biomarker stands out in the field. Immune parameters including cytokines and other acute phase proteins are indicative to the risk of post-stroke infections but have also been associated to functional outcome after stroke ([@B8]).

We aimed to investigate a range of inflammation-, immunity-, and stress-related biomarkers in a cohort of patients without stroke-associated infections regarding their predictive abilities for functional outcome and explore whether they correlate with MRI markers, such as infarct size or location.

Methods {#s2}
=======

We combined the clinical and radiological data of patients participating in two observational acute stroke cohorts: the PREDICT and 1000Plus studies (clinicaltrials.gov NCT01079728 and NCT00715533). Both studies received full approval by the institutional ethics\' committee, including the pooling of data for combined analysis. All patients (or if necessary, their legal representatives) gave informed consent to participation. Protocol details of both studies have been previously published ([@B9], [@B10]). Briefly, both studies recruited acute ischemic stroke patients to investigate either the prediction of stroke-associated pneumonia (PREDICT) or the natural course of multimodal MRI parameters (1000Plus), especially the evolution of DWI-perfusion imaging-mismatch. There was significant overlap of visit time points throughout the course of the study (see [Figure 1](#F1){ref-type="fig"}). PREDICT was a multicentric study, with one of the participating centers (Charité Campus Benjamin Franklin) being the only study site in the 1000Plus study. PREDICT recruited 189 patients on that common site, 94 of which also participating in the 1000Plus study. We excluded patients suffering from an infection during their time of hospital admission for this analysis.

![Timeline of the two studies supporting this analysis **(A)** and study flow chart **(B)**.](fneur-10-00083-g0001){#F1}

Blood samples parameters were obtained within the first 4 days of hospital admission. Samples were immediately post-processed and then frozen at −80°C in order to allow for batch analyses at the end of the study. Serum levels of mid-regional pro atrial natriuretic peptide (MRproANP), mid-regional pro adrenomedullin (MRproADM), C-terminal pro endothelin (CTproET), ultrasensitive copeptin (CPus), and ultrasensitive procalcitonin (PCTus) were measured using fluorescent immunoassays on the automated BRAHMS KRYPTOR compact PLUS™ analyzer (BRAHMS GmbH/Thermo Fisher Scientific, Henningsdorf, Germany) according to the manufacturer\'s protocol. The lower limits of quantitation were 4.5 pmol/l for MRproANP, 0.05 nmol/l for MRproADM, 3 pmol/l for CTproET, 1.9 pmol/l for CPus, and 0,02 μg/l for PCTus. Plasma concentrations of IL-6, IL-8, IL-10, and LBP were determined with the IMMULITE™ semi-automatic chemiluminescent immunoassay (Siemens Medical Solutions, Bad Nauheim, Germany). The detection limit for IL-6 and IL-8 is 2, 1 pg/ml for IL-10 and 0.8 μg/ml for LBP. Expression of human leukocyte antigen-DR (HLA-DR) on monocytes was determined in EDTA whole blood samples by flow cytometry using a highly standardized quantitative assay, as described earlier ([@B9]).

Multiparametric stroke MRI was performed on a 3T scanner (Tim Trio; Siemens AG, Erlangen, Germany) at admission (always within 24 h of the event), the following day and lastly 4--6 days after the event. Applied sequences contained T2^\*^, DWI, FLAIR, TOF-MRA, and for the first two imaging time points also perfusion imaging. For further detail please refer to the published protocol ([@B10]). Admission MRI was performed as initial imaging upon presentation, or if outside of regular hours as the first examination the next morning. Follow-up MRIs were performed in the morning of the respective days. Blood samples were collected for the first day as soon as the patients and/or their legal representatives consented. The following samples were drawn with the routine laboratory rounds in the morning. Hence, delay between imaging and blood sampling was kept as short as logistically possible.

Standard descriptive sum statistics were used to describe demographics and stroke characteristics as well as biomarker and imaging results. Associations were analyzed by use of Fischer\'s exact test, independent samples *t-*test and Spearmans correlation, depending on character of variables. Alpha-error level was set at 2-tailed *p* = 0.05. All statistics were performed using SPSS (version 24.0, IBM, Armonk, NY, USA). In view of the small sample size and the explorative nature of the study, we decided against statistical correction such as Bonferroni.

Results {#s3}
=======

We identified 94 patients participating in both Predict and 1000Plus. Three of them suffered from an infection during the course of their hospital stay and were excluded from this analysis (see [Figure 1B](#F1){ref-type="fig"} for further detail). Mean age was 68 years (SD 10.5) and 32.2% of subjects were female. Median NIHSS score at admission was 3 (IQR 2--5). At 3 months, median mRS was 1 (IQR 0--2). Thrombolysis was applied in 23% of patients. For further details on clinical syndrome on admission, risk factors and stroke etiology refer to [Table 1](#T1){ref-type="table"}.

###### 

Demographics and clinical stroke characteristics.

  ***n***                                        **91**
  ---------------------------------------------- -------------
  Sex, *n* (%) female                            29 (32.2)
  Age, years, mean (SD)                          68.0 (10.5)
  Admission NIHSS, median (IQR)                  3 (2-5)
  Admission mRS, median (IQR)                    2 (1-3)
  **ADMISSION SYMPTOMS**                         
  Aphasia \[7\]                                  10 (11.9)
  Motor deficit                                  67 (77.9)
  Dysarthria \[7\]                               46 (54.8)
  Dysphagia \[11\]                               5 (6.3)
  **RISK FACTORS**                               
  Diabetes mellitus                              25 (28.7)
  Atrial fibrillation                            14 (16.1)
  Previous stroke                                16 (18.4)
  Arterial hypertension                          74 (85.1)
  Hyperlipidemia                                 55 (63.2)
  Smoking \[61\]                                 5 (16.1)
  Thrombolysis                                   20 (23.0)
  **TOAST**                                      
  Large artery occlusion                         56 (64.4)
  Cardioembolism                                 18 (20.7)
  Small artery disease                           6 (6.9)
  Other etiology                                 3 (3.4)
  Unknown etiology                               3 (3.4)
  Concurring etiology                            1 (1.1)
  mRS 90 days after event, median (IQR) \[17\]   1 (0--2)

*Values given are n (%) if not explicitly stated otherwise, missing cases reported if \>5 as \[n\]. NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin Scale; TOAST, Trial of Org10172 in Acute Stroke Treatment*.

Initial MRI was performed at a median of 549.5 min (IQR 130.25--860) after event. Mean volume of DWI lesion at admission was 5.7 ml (SD 12.8), mean final infarct volume as measured on FLAIR was 10 ml (SD 14.9). The right hemisphere was more frequently affected than the left hemisphere (52 vs. 37%) and cortex was involved in 61% of infarctions. Blood samples were collected during the first 4 days of hospitalization after stroke, and values for day of admission as well as maximum/minimum values are outlined in [Table 2](#T2){ref-type="table"}.

###### 

Imaging and blood-based biomarker results.

  **Hemisphere of DWI lesion**                  
  --------------------------------------------- -------------------------
  Right                                         46 (51.7)
  Left                                          32 (36.0)
  Bilateral                                     11 (12.4)
  DWI lesion volume on acute MRI, ml            5.7 (12.8)
  PI deficit volume on acute MRI, ml            45.1 (78.0)
  DWI-PI mismatch on acute MRI, ml              26.4 (58.5)
  **TYPE OF INFARCTION**                        
  Territorial                                   76 (85.4)
  Lacunar infarction                            12 (13.5)
  Borderzone infarction                         1 (1.1)
  **REGIONS AFFECTED**                          
  Any Cortex                                    54 (60.7)
  Caudate                                       3 (3.3)
  Lenticulate                                   4 (4.4)
  Capsula interna                               8 (8.8)
  Insula                                        11 (12.1)
  ASPECT M1                                     6 (6.6)
  ASPECT M2                                     17 (18.7)
  ASPECT M3                                     14 (15.4)
  ASPECT M4                                     15 (16.5)
  ASPECT M5                                     34 (37.4)
  ASPECT M6                                     21 (23.1)
  FLAIR lesion volume on Follow Up, ml \[33\]   10.0 (14.9)
  **HLA-DR, EPITOPES/CELL, MEDIAN (IQR)**       
  At inclusion \[3\]                            18,387 (14,434--25,788)
  Lowest \[1\]                                  16,505 (11,386--21,285)
  **IL-6, PG/ML, MEDIAN (IQR)**                 
  At inclusion \[3\]                            2.8 (2.0--5.2)
  Highest \[1\]                                 5.2 (2.7--11.0)
  **IL-8, PG/ML, MEDIAN (IQR)**                 
  At inclusion \[3\]                            5.0 (5.0--5.0)
  Highest \[1\]                                 5.0 (5.0--5.2)
  **IL-10, PG/ML, MEDIAN (IQR)**                
  At inclusion \[3\]                            5.0 (5.0--5.0)
  Highest \[1\]                                 5.0 (5.0--5.0)
  **LBP**, **μG/ML, MEDIAN (IQR)**              
  At inclusion \[3\]                            7.23 (5.48--9.34)
  Highest \[1\]                                 8.90 (6.68--11.65)
  **MPproANP, PG/ML, MEDIAN (IQR)**             
  At inclusion \[29\]                           111.4 (65.5--180.9)
  Highest \[23\]                                122.5 (79.1--195.8)
  **MPproADM, PG/ML, MEDIAN (IQR)**             
  At inclusion \[29\]                           0.703 (0.593--0.868)
  Highest \[22\]                                0.751 (0.613--0.917)
  **CTproET, PG/ML, MEDIAN (IQR)**              
  At inclusion \[30\]                           61.4 (50.7--75.9)
  Highest \[22\]                                64.4 (54.6--83.1)
  **CPus, PG/ML, MEDIAN (IQR)**                 
  At inclusion \[29\]                           8.84 (5.27--14.22)
  Highest \[22\]                                10.19 (5.60--17.40)
  **PCT us, PG/ML, MEDIAN (IQR)**               
  At inclusion \[30\]                           0.031 (0.024--0.041)
  Highest \[23\]                                0.039 (0.028--0.050)

*Values given are n (%) if not explicitly stated otherwise, missing cases reported if \>5 as \[n\]. HLA-DR, Human leukocyte antigen expression on monocytes; IL-6, IL-8, IL-10, three interleukins; LBP, lipopolysaccharide-binding protein; MRproANP, mid-regional pro atrial natriuretic peptide; MRproADM, mid-regional pro adrenomedullin; CTproET, C-terminal pro endothelin; CPus, ultrasensitive copeptin; PCTus, ultrasensitive procalcitonin*.

Age of patients was associated with IL-6, MRproANP, MRproADM, and CTproET. Stroke severity at admission as measured by National Institute of Health Stroke Scale (NIHSS) score was associated with IL-6. Functional outcome as measured by modified Rankin Scale (mRS) at day 90 was associated with admission levels of ultrasensitive Copeptin, maximum MRproADM, IL-6, and minimum HLA-DR levels ([Table 3](#T3){ref-type="table"}).

###### 

Association of biomarkers at inclusion and lowest/highest measurement with clinical parameters.

                            **Aphasia**   **Motor deficit**   **Dysarthria**   **Dysphagia**   **Sex**   **NIHSS**   **mRS d90**   **Age**
  ------------- ----------- ------------- ------------------- ---------------- --------------- --------- ----------- ------------- --------------
  HLA-DR        Inclusion   0.405         0.979               0.548            0.757           0.606     0.409       0.052         0.249
                Lowest      0.987         0.436               0.959            0.173           0.340     0.099       **0.030**     0.069
  IL-6          Inclusion   0.410         0.478               0.912            0.739           0.824     **0.005**   0.252         **0.001**
                Highest     0.369         0.281               0.983            0.438           0.884     **0.005**   **0.015**     **0.030**
  IL-8          Inclusion   0.443         **0.050**           0.640            0.552           0.803     0.073       0.226         0.339
                Highest     0.633         0.393               0.386            0.467           0.597     0.331       0.683         0.566
  IL-10         Inclusion   0.416         0.468               0.136            0.611           0.564     0.916       0.248         0.460
                Highest     0.247         0.360               0.257            0.727           0.989     0.683       0.587         0.236
  LBP           Inclusion   0.086         0.364               0.958            0.660           0.227     0.291       0.952         0.148
                Highest     0.857         0.861               0.442            0.353           0.621     0.062       0.637         0.152
  MPproANP      Inclusion   0.486         0.640               **0.012**        **0.029**       0.914     0.163       0.654         **0.005**
                Highest     0.521         0.287               **0.047**        **0.005**       0.926     0.068       0.911         **0.005**
  MPproADM      Inclusion   **0.001**     0.320               0.310            0.915           0.296     0.241       0.264         **\< 0.001**
                Highest     0.351         0.209               0.618            0.979           0.547     0.158       **0.043**     **0.001**
  CTproET       Inclusion   0.398         0.323               0.613            0.994           0.962     0.160       0.344         **0.018**
                Highest     **0.015**     0.330               0.893            0.888           0.933     0.092       0.169         **0.039**
  Copeptin us   Inclusion   0.720         0.455               0.548            0.436           0.357     0.768       **0.006**     0.540
                Highest     0.335         0.910               0.354            0.441           0.115     0.918       0.144         0.298
  PCT us        Inclusion   0.643         0.381               **0.007**        0.736           0.286     0.254       0.962         0.975
                Highest     0.855         0.560               0.056            0.908           0.362     0.634       0.230         0.711

*Values given are two-sided p-values obtained by a students\' t-test; Bold text denotes significant associations; HLA-DR, Human leukocyte antigen expression on monocytes; IL-6, IL-8, IL-10, three interleukins; LBP, lipopolysaccharide-binding protein; MRproANP, mid-regional pro atrial natriuretic peptide; MRproADM, mid-regional pro adrenomedullin; CTproET, C-terminal pro endothelin; CPus, ultrasensitive copeptin; PCTus, ultrasensitive procalcitonin*.

Acute volume of DWI restriction on admission MRI scans was moderately correlated to admission (Spearman\'s ρ 0.336) and maximum (Spearman\'s ρ 0.276) IL-6 as well as maximum LBP (Spearman\'s ρ 0.222) levels. Extent of perfusion imaging (PI) deficit and DWI-PI-Mismatch were moderately correlated to admission (Spearman\'s ρ 0.306 and 0.231, respectively) and maximum (Spearman\'s ρ 0.277 and 0.215, respectively) IL-6 levels. Final lesion volume on FLAIR was moderately correlated to admission IL-6 levels (Spearman\'s ρ 0.364) ([Table 4](#T4){ref-type="table"}). Cortical infarcts were associated with higher IL-6 levels at admission. By use of the ASPECT scoring system we only found inconsistent associations of biomarker levels with infarct location ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

###### 

Association of biomarkers at inclusion and lowest/highest measurement with imaging parameters.

                               **Initial DWI volume**   **Initial PI deficit**   **Initial mismatch**   **Final FLAIR volume**
  ------------- -------------- ------------------------ ------------------------ ---------------------- ------------------------
  HLA-DR        At Inclusion   0.933                    0.936                    0.716                  0.397
                Lowest         0.678                    0.234                    0.443                  0.300
  IL-6          At Inclusion   **0.002**                **0.016**                **0.030**              **0.006**
                Highest        **0.009**                **0.029**                **0.042**              0.383
  IL-8          At Inclusion   0.955                    0.667                    0.928                  0.068
                Highest        0.787                    0.798                    0.099                  0.347
  IL-10         At Inclusion   0.290                    0.555                    0.701                  0.822
                Highest        0.081                    0.101                    0.595                  0.435
  LBP           At Inclusion   0.084                    0.877                    0.625                  0.546
                Highest        **0.037**                0.349                    0.431                  0.688
  MPproANP      At Inclusion   0.949                    0.945                    0.566                  0.830
                Highest        0.853                    0.795                    0.486                  0.941
  MPproADM      At Inclusion   0.882                    0.901                    0.123                  0.130
                Highest        0.682                    0.801                    0.267                  0.340
  CTproET       At Inclusion   0.923                    0.887                    0.665                  0.827
                Highest        0.834                    0.906                    0.541                  0.849
  Copeptin us   At Inclusion   0.144                    0.801                    0.457                  0.701
                Highest        0.487                    0.673                    0.648                  0.815
  PCT us        At Inclusion   0.804                    0.214                    0.224                  0.637
                Highest        0.418                    0.151                    0.381                  0.513

*Values given are two-sided p-values obtained by a Spearman\'s correlation; Bold text denotes significant associations; HLA-DR, Human leukocyte antigen expression on monocytes; IL-6, IL-8, IL-10, three interleukins; LBP, lipopolysaccharide-binding protein; MRproANP, mid-regional pro atrial natriuretic peptide; MRproADM, mid-regional pro adrenomedullin; CTproET, C-terminal pro endothelin; CPus, ultrasensitive copeptin; PCTus, ultrasensitive procalcitonin*.

Discussion {#s4}
==========

We examined the relationship of inflammatory, immune, and stress biomarkers with MRI parameters in 91 stroke patients not suffering from stroke-associated infections during the course of the study. Interleukin-6 was associated with infarct size and tissue at risk, as well as final infarct volume. The other studied biomarkers did not show any associations with imaging markers in the absence of infection. Overall, the studied cohort was rather mildly affected by stroke (median admission NIHSS 3 IQR 2--5 and 3 months mRS 1 IQR 0--2).

The biological role of IL-6 in ischemic stroke remains uncertain. Astrocytes and microglia express IL-6, but whether it primarily exerts neurotoxic or---protective effects is a matter of scientific discourse ([@B11], [@B12]). Our study found a significant association of IL-6 levels with NIHSS scores at admission, although Spearman\'s ρ only showed moderate correlation. Furthermore, we found a significant correlation of IL-6 levels with lesion volume, whether on DWI scans at admission, PI deficit, DWI-PI mismatch or on follow-up FLAIR images, which is in line with the association of IL-6 levels and NIHSS scores at admission. Infarct size has previously been reported to correlate at least with intrathecal levels, but not consistently with serum levels, of IL-6 ([@B13]--[@B15]). IL-6 was repeatedly associated with poor functional outcome, but whether this is an independent effect or a signal due to infection remains unclear ([@B8]). Our data shows a significant association of IL-6 with functional outcome as measured by mRS in a cohort of patients not suffering from infection, further corroborating an association independent of infections. IL-6 has been previously linked to small vessel disease and silent cerebral infarctions ([@B16]--[@B18]). IL-6 and also IL-10 were associated with the presence of diffusion-perfusion- or clinical-diffusion-mismatch on acute stroke MRI ([@B19]--[@B21]). Furthermore, cortical infarcts were associated with IL-6. The associations of several other biomarkers with localization of lesions have to be interpreted with caution considering the sample size and plausibility.

Interestingly, in our cohort of patients not suffering from infections, plasma levels of IL-8 and IL-10 were mostly not detectable and below the upper limit of normal (5.0 pg/ml). This is in line with previous findings by us and Chamorro et al. showing increased IL-10 levels in patients with stroke-associated infections ([@B22], [@B23]). These cytokines may therefore be mainly triggered by systemic inflammation in the course of infectious complications after stroke, whereas neuroinflammation within the CNS does not seem to trigger their expression.

As previously described, we found functional outcome after 3 months to be inversely correlated to HLA-DR ([@B24]), and furthermore correlated to MRproADM and ultrasensitive Copeptin. Expression of monocytic HLA-DR is a marker of monocyte activation and has been shown to be a key marker for stroke-induced immune depression ([@B9], [@B25]). Lower HLA-DR expression is a strong predictor of stroke-associated pneumonia and is associated with worse functional outcome ([@B9], [@B24]). The latter association is further corroborated in our data independent of infection.

Several biomarkers showed an association with age, and while this has previously been reported for CTproET ([@B26]) and appears plausible for a vascular stress marker as MRproANP, the relationship for MRproADM and IL-6 is less seemingly obvious. LBP is a marker of bacterial translocation and higher levels are found in patients with post-stroke infection ([@B27]). It is also associated with a worse short-term stroke outcome ([@B28]). We could not reproduce this finding in stroke patients not suffering from infection or show any association with imaging characteristics. MRproANP is used as a biomarker for hemodynamic stress and was previously shown to indicate higher risk for ischemic stroke ([@B29]). There were no significant associations with imaging characteristics or functional outcome in our cohort. MRproADM exerts vasodilating, vasoprotective, and angiogenic effects and is associated with post-stroke infections ([@B30]) and functional outcome after stroke ([@B31]). MRproADM has been associated with progression of small vessel disease accompanying cognitive decline ([@B32]). We could not reproduce the association with poor outcome or find an association with imaging characteristics. The vasopressin surrogate CP has been associated with higher risk of all-cause mortality, poor functional outcome and infections after ischemic stroke ([@B33]--[@B36]). Furthermore, it has been proposed to improve prediction of recurring cerebrovascular events ([@B37]). CTproET is influenced by age, renal function, and hemodynamic parameters of healthy subjects, and is a strong vasoconstrictor ([@B26]). While it has not been studied as biomarker in ischemic stroke before, its derivative endothelin has been associated with carotid atherosclerosis and silent cerebral infarctions ([@B38]). Both biomarkers were not associated with outcome in our cohort, and did not show any significant correlations with imaging findings. PCT is a blood-based marker for infection in general and was shown to be associated with post-stroke infections and functional outcome ([@B36], [@B39], [@B40]). Furthermore, higher levels of PCT are associated with extent of small vessel disease and silent infarctions on MRI ([@B41]). Our data did not show an association with functional outcome or imaging characteristics.

Our study suffers from several limitations: the sample size, while average for a study in this field, is limited, especially considering the amount of analyses performed. While multiple testing was a concern for us, the purpose of this study was purely exploratory. Our findings need to be corroborated by further confirmatory studies. Furthermore, our study cohort was overall rather mildly affected by stroke, not necessarily reflecting a cohort of severely impaired patients. Strengths of this report are the prospective collection of data with an in-depth clinical and neuroradiological assessment during the acute course of the disease avoiding recall H bias.

Our data supports the conclusion that IL-6 is an inflammatory marker of cerebral parenchymal damage independent of systemic infections.
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